What’s in Astrazeneca Plc (NYSE:AZN) After Decline in Shorted Shares?

December 7, 2017 - By Linda Rogers

 What’s in Astrazeneca Plc (NYSE:AZN) After Decline in Shorted Shares?

The stock of Astrazeneca Plc (NYSE:AZN) registered a decrease of 11.84% in short interest. AZN’s total short interest was 14.88M shares in December as published by FINRA. Its down 11.84% from 16.88M shares, reported previously. With 3.58 million shares average volume, it will take short sellers 4 days to cover their AZN’s short positions. The short interest to Astrazeneca Plc’s float is 0.6%.

The stock increased 0.41% or $0.13 during the last trading session, reaching $32.22. About 3.48 million shares traded. AstraZeneca PLC (NYSE:AZN) has risen 19.45% since December 7, 2016 and is uptrending. It has outperformed by 2.75% the S&P500.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. The company has market cap of $78.65 billion. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. It has a 21.13 P/E ratio. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

AstraZeneca PLC (NYSE:AZN) Ratings Coverage

Among 24 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 14 have Buy rating, 0 Sell and 10 Hold. Therefore 58% are positive. AstraZeneca plc (ADR) had 39 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of AstraZeneca PLC (NYSE:AZN) earned “Neutral” rating by Credit Suisse on Friday, May 12. The stock of AstraZeneca PLC (NYSE:AZN) has “Hold” rating given on Thursday, July 27 by Cowen & Co. The stock of AstraZeneca PLC (NYSE:AZN) has “Hold” rating given on Monday, October 16 by Cowen & Co. The rating was downgraded by Leerink Swann to “Hold” on Thursday, July 27. On Wednesday, October 18 the stock rating was maintained by Citigroup with “Buy”. The stock has “Market Perform” rating by Leerink Swann on Monday, October 23. On Friday, September 18 the stock rating was upgraded by Bryan Garnier & Cie to “Buy”. BMO Capital Markets initiated the shares of AZN in report on Wednesday, September 6 with “Buy” rating. Morgan Stanley upgraded the shares of AZN in report on Tuesday, December 1 to “Overweight” rating. The company was maintained on Thursday, September 14 by BMO Capital Markets.

More important recent AstraZeneca PLC (NYSE:AZN) news were published by: Investorplace.com which released: “AstraZeneca plc (ADR) (AZN) Stock Tanks on Lung Cancer Drug Disappointment” on July 27, 2017, also Investorplace.com published article titled: “Why AstraZeneca plc (ADR) (AZN), Advanced Micro Devices, Inc. (AMD) and Spirit …”, Investorplace.com published: “AstraZeneca plc (ADR) (AZN) Shares Soar on Lung Cancer Drug Success” on May 12, 2017. More interesting news about AstraZeneca PLC (NYSE:AZN) was released by: Marketwatch.com and their article: “AstraZeneca: FDA grants Imfinzi priority review” with publication date: October 17, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.